We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, two of our programs are focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury.
Latest Financial Results
Quarter Ended Mar 31, 2023
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2022
Receive updates straight into your inbox
Unicycive Therapeutics, Inc.
4300 El Camino Real
Los Altos, CA 94022
Philadelphia Stock Transfer, Inc.
2320 Haverford Road
Ardmore, PA 19003